Shiqun Sun

Shiqun Sun

Auto-generated profile, based on publicly available information

Shiqun Sun

Shanghai Jiao Tong University School of Medicine

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 January 2017 in Oxidative Medicine and Cellular Longevity
Verified
Journal Article
Open access
PDF file
XWXiao-Lei Wang
Xiao-Lei Wang
TZTuo Zhang
Tuo Zhang
LHLiu-Hua Hu
Liu-Hua Hu
SSShi-Qun Sun
Shi-Qun Sun
WZWei-Feng Zhang
Wei-Feng Zhang
BHBen He
Ben He
Statins are a promising new strategy to prevent contrast‐induced acute kidney injury (CI‐AKI). In this study we compared the ameliorative effect of different statins in a rat model of CI‐AKI. Sprague‐Dawley rats were divided into five groups: control group; CI‐AKI group; CI‐AKI + rosuvastatin group (10 mg/kg/day); CI‐AKI + simvastatin group (80 mg/kg/day); and CI‐AKI + atorvastatin group (20 mg/kg/day). CI‐AKI was induced by dehydration for 72 hours, followed by furosemide intramuscular injection 20 minutes before low‐osmolar contrast media (CM) intravenous injection. Statins were administered by oral gavage once daily for 3 consecutive days before CM injection and once 4 hours after CM injection. Rats were sacrificed 24 hours after CM injection, and renal function, kidney histopathology, nitric oxide (NO) metabolites, and markers of oxidative stress, inflammation, and apoptosis were evaluated. The results showed that atorvastatin and rosuvastatin but not simvastatin ameliorated CM‐induced serum creatinine elevation and histopathological alterations. Atorvastatin and rosuvastatin showed similar effectiveness against CM‐induced oxidative stress, but simvastatin was less effective. Atorvastatin was most effective against NO system dysfunction and cell apoptosis, whereas rosuvastatin was most effective against inflammation. Our findings indicate that statins exhibit differential effects in preventing CI‐AKI when given at equivalent lipid‐lowering doses.

6 May 2025 in Journal of the American Heart Association
Verified
Journal Article
Open access
XCXian Cui
Xian Cui
SSShiqun Sun
Shiqun Sun
HZHui Zhang
Hui Zhang
YGYulu Gong
Yulu Gong
DHDarong Hao
Darong Hao
XLXiangwei Li
Xiangwei Li
Background: Several DNA methylation (DNAm) algorithms have recently emerged as robust predictors of aging and adverse health outcomes in older adults, offering valuable insights into cardiovascular disease (CVD) risk stratification. However, their predictive performance for CVD varies significantly. This study aimed to systematically investigate the associations of 12 widely used DNAm algorithms with CVD and mortality risk. Methods: Data from the NHANES (National Health and Nutrition Examination Survey) 1999 to 2002 were used to assess 12 DNAm algorithms (eg, HannumAgeacc, PhenoAgeacc, GrimAgeMortacc, GrimAge2Mortacc) in relation to CVD risk and mortality. Two cohorts were analyzed: one for CVD risk (n=1230) and another for CVD mortality risk (n=1606). DNAm was measured using the Infinium Methylation EPIC BeadChip kit (Illumina). Odds ratios (ORs) and hazard ratios (HRs), along with 95% CIs per SD increase of these DNAm algorithms, were calculated. Results: Significant associations were observed for GrimAgeMortacc and GrimAge2Mortacc with coronary heart disease and heart attack, with multivariable‐adjusted ORs per SD increase ranging from 2.15 to 2.76. However, several algorithms exhibited no significant association with self‐reported prevalent CVD. For mortality risk, HannumAgeacc, PhenoAgeacc, ZhangAgeacc, GrimAgeMortacc, and GrimAge2Mortacc were significantly associated with CVD mortality. The multivariable‐adjusted HRs per SD increase were 1.19 (95% CIs, 1.05–1.34), 1.13 (95% CIs, 1.01–1.26), 1.63 (95% CI, 1.08–2.47), 1.90 (95% CIs, 1.51–2.40), and 1.87 (95% CIs, 1.51–2.32), respectively. These associations were consistent across biological sex, age (≥50 and <65 versus ≥65 years), and race and ethnicity groups. Conclusions: DNAm algorithms, particularly GrimAgeMortacc and GrimAge2Mortacc, may serve as valuable tools for CVD risk stratification and mortality risk assessment.

2 December 2025 in Journal of the American Heart Association
Verified
Journal Article
Open access
XCXian Cui
Xian Cui
CYChunbei Yi
Chunbei Yi
HZHui Zhang
Hui Zhang
YXYaqian Xu
Yaqian Xu
CDChongyu Ding
Chongyu Ding
XLXiangwei Li
Xiangwei Li
Background: While DNA methylation ( DNAm )‐based algorithms of aging show promise for predicting age‐related diseases, their comparative utility for incident cardiovascular disease ( CVD ) remains underexplored. We aimed to systematically compare 13 DNAm algorithms in relation to CVD risk in older adults. Methods: This prospective cohort study included 2112 participants from the US HRS (Health and Retirement Study) with baseline DNAm data (2016) and 6‐year follow‐up. DNAm profiling was performed using the Infinium MethylationEPIC BeadChip kit ( EPIC , Illumina, San Diego, CA ). Thirteen widely used DNAm algorithms of aging were evaluated. Cox proportional hazards models were used to estimate hazard ratios (HRs) and 95% CIs per 1‐SD increase in risk scores for incident CVD, including any CVD, congestive heart failure, and stroke. Results: During a median of 37 months’ follow‐up, a total of 288 CVD cases (congestive heart failure, 38; stroke, 152) were observed. Zhang_DNAmAge, methylation Pace of Aging, and DNAmGrimAgeAcc showed positive associations with any CVD risk, with HRs per SD increase of 1.25 (95% CI, 1.07–1.45), 1.16 (95% CI, 1.02–1.33), and 1.24 (95% CI, 1.05–1.47), respectively. For specific CVD subtypes, DNAmGrimAge was associated with congestive heart failure risk ( HR , 1.47 [95% CI, 1.11–1.95]), while both mPoA ( HR , 1.24 [95% CI, 1.03–1.49]) and HorvathAcc ( HR , 1.28 [95% CI , 1.07–1.55]) predicted incident stroke. Significant dose–response relationships ( P ‐trend <0.05) were observed for Zhang_DNAmAge and DNAmGrimAgeAcc across all CVD outcomes. Conclusions: Zhang_DNAmAge, methylation Pace of Aging, and DNAmGrimAgeAcc function as independent predictors of incident CVD . These epigenetic biomarkers may improve early CVD detection and risk stratification in aging populations.